 NEW YORK, Oct. 05, 2022 GLOBE NEWSWIRE -- Cellectis the Company Euronext Growth: ALCLS - NASDAQ: CLLS, a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today that pre-clinical data on TALEN-edited smart CAR T-cells to overcome key challenges of targeting solid tumors, will be presented at the Society for Immunotherapy of Cancers 37th Annual Meeting SITC 2022, to be held in Boston, M.A. and virtually on November 8-12, 2022. 